Clinical Scorecard: Blood Pressure Variability Across Visits and Its Impact on Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis
At a Glance
Category
Detail
Condition
Visit-to-visit blood pressure variability (VVV BPV) as a risk factor for cardiovascular disease (CVD)
Key Mechanisms
Fluctuations in blood pressure over multiple clinical visits independently predict hypertensive target organ damage and cardiovascular events
Target Population
Adults with or without comorbidities such as diabetes mellitus, chronic kidney disease, and hypertension
Care Setting
Primary care and clinical settings utilizing electronic health records (EHR) and non-EHR data sources
Key Highlights
VVV BPV is an independent predictor of cardiovascular disease outcomes including myocardial infarction, stroke, heart failure, and cardiovascular mortality.
Blood pressure variability estimates from electronic health records are comparable in predictive value to those from non-EHR sources.
A visit-to-visit BPV threshold of standard deviation ≥6.72 mmHg or coefficient of variation ≥9.05% is associated with a 10% increased risk of cardiovascular events.
Use standardized BPV metrics such as standard deviation (SD) and coefficient of variation (CV) to quantify BP variability.
Management
Recognize elevated VVV BPV as a modifiable risk factor for cardiovascular disease beyond mean blood pressure levels.
Develop strategies to address and reduce BP variability in hypertensive patients to mitigate cardiovascular risk.
Monitoring & Follow-up
Utilize electronic health record data to reliably estimate visit-to-visit BP variability over time.
Monitor BP variability longitudinally using consistent measurement protocols to improve risk stratification.
Risks
Elevated visit-to-visit BP variability increases the risk of cardiovascular events by approximately 10% at identified thresholds.
Ignoring BP variability may lead to underestimation of cardiovascular risk despite controlled mean blood pressure.
Patient & Prescribing Data
Adults undergoing routine blood pressure monitoring in clinical practice, including those with hypertension and related comorbidities.
Patients with BPV exceeding SD 6.72 mmHg or CV 9.05% should be considered at higher cardiovascular risk, warranting closer monitoring and potential therapeutic adjustment.
Clinical Best Practices
Standardize blood pressure measurement protocols across clinical visits to reduce measurement bias and improve BPV assessment accuracy.
Incorporate BP variability metrics into electronic health record systems to facilitate automated risk stratification.
Educate clinicians on the prognostic significance of visit-to-visit BP variability to enhance clinical decision-making.
Further research is needed to develop and implement effective interventions targeting BP variability reduction.
